MECASERMIN

( DrugBank: Mecasermin / KEGG DRUG: Mecasermin, Mecasermin rinfabate )


5 diseases
IDDisease name (Link within this page)Number of trials
78Hypopituitarism0
96Crohn disease1
168Ehlers-Danlos syndrome1
IDDisease name (Link within this page)Number of trials
265Lipodystrophy1
299Cystic fibrosis1

78. Hypopituitarism


Clinical trials : 34Drugs : 44 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 19 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,737Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

168. Ehlers-Danlos syndrome


Clinical trials : 16Drugs : 22 - (DrugBank : 10) / Drug target genes : 11 - Drug target pathways : 103 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

265. Lipodystrophy


Clinical trials : 127Drugs : 137 - (DrugBank : 58) / Drug target genes : 28 - Drug target pathways : 99 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,826Drugs : 1,271 - (DrugBank : 246) / Drug target genes : 118 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries